Leukemia Research
ISSN 0145-2126 · Elsevier BV · United Kingdom · active 1977–2026
Metrics
- Best Scimago quartile (2025)
- Q2
- Cites per paper (2y)
- 1.1
- SJR
- 0.876
- h-index
- 117
“Cites per paper” is a two-year cited-by rate computed from OpenAlex. It is not a Clarivate Journal Impact Factor — we neither compute nor license that metric (how the two differ). Citation rates differ enormously between fields, so compare within a discipline. What the other figures mean: journal quartile, SJR, h-index and article processing charge.
Data as of 15 November 2026 (venue index build).
Scimago Journal Rank 2025
In the Scimago Journal Rank 2025 edition, Leukemia Research is Q2 in 2 of its 3 subject categories and Q3 in the other 1. Its best category quartile is Q2.
| Subject category | Quartile | Rank in category |
|---|---|---|
| Hematology | Q2 | #51 of 151 |
| Oncology | Q2 | #173 of 426 |
| Cancer Research | Q3 | #127 of 235 |
- Cites per document (2 years, Scopus)
- 1.92
- Documents indexed in 2025 (Scopus)
- 96
OpenAlex counts about 1.1 citations per paper over two years; Scopus, through Scimago, counts 1.92 per document. The two databases index different journals, documents and citations, so the figures differ. Neither is a Clarivate Journal Impact Factor.
The quartile is the one Scimago prints for each category. Rank is the journal's position by SJR among the journals Scimago lists in that category (#1 is the highest); “—” means we hold no rank consistent with that quartile. The document count is what Scopus indexed that year, which can be lower than a journal's full output. Source: SCImago Journal Rank 2025 edition, from Scopus data (scimagojr.com, CC BY-NC).
Leukemia Research is Q2 in 2 of its 3 Scimago subject categories (2025 edition; best category Hematology: Q2, #51 of 151), with SJR 0.876 (Scimago) and an h-index of 117 (OpenAlex). Listed in Scopus, Web of Science, PubMed.
Is this the right journal for your paper?
The AI Journal Finder ranks the best-matched journals for your paper’s topic — with tier, open access, citation rate and predatory flags. Free to start.
Indexing & access
- Indexed in
- ScopusWeb of SciencePubMed
- Access status:
- hybrid. Where this comes from publisher-level signals rather than works-level data it is a heuristic — confirm on the journal’s own site, especially regarding any article processing charge.
Scope
Frequently asked
Is Leukemia Research a predatory journal?
Our screening does not flag Leukemia Research. That is not a guarantee of quality — it means the venue is not on Beall's archive (frozen since 2017) and does not match our name-pattern heuristic. It is listed in Scopus, Web of Science, PubMed, which is a positive signal.
Is Leukemia Research indexed in Scopus or Web of Science?
Per our venue index, Leukemia Research appears in: Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.
What is the impact factor of Leukemia Research?
Papers in Leukemia Research are cited about 1.1 times each within two years of publication, and Scimago places it in Q2, with an h-index of 117. Those are the open equivalents: the Clarivate Journal Impact Factor is a proprietary metric we neither compute nor license, so we show the two-year citation rate and Scimago quartile instead — they answer the same question of how heavily the journal is cited. A citation rate is a property of a field as much as of a journal.
What Scimago quartile is Leukemia Research (Q1, Q2, Q3, or Q4)?
In the Scimago Journal Rank 2025 edition, Leukemia Research is Q2 in 2 of its 3 subject categories and Q3 in the other 1. By category: Hematology: Q2, #51 of 151; Oncology: Q2, #173 of 426; Cancer Research: Q3, #127 of 235. Its best category quartile is Q2. Quartiles split the journals in a subject category into four equal groups by SJR, so Q1 is the most-cited quarter and Q4 the least; Leukemia Research is cited about 1.1 times per paper over two years, with an h-index of 117.
What is the Web of Science (JCR) quartile of Leukemia Research?
The Web of Science quartile comes from Clarivate's Journal Citation Reports (JCR), a proprietary product we neither license nor compute — so we cannot state a JCR quartile for Leukemia Research. The open equivalent is its best Scimago quartile, Q2 in Hematology and 1 other category, derived from Scopus citation data. Because JCR ranks against Web of Science and Scimago against Scopus, the two can differ, so check Clarivate's site directly if you need the JCR quartile specifically.
Is Leukemia Research open access?
Our index records its access status as "hybrid". Where this is derived from publisher-level signals rather than works-level data it is a heuristic, so confirm on the journal's own site — particularly if an article processing charge matters to you.
Ready to submit? Tools for your next paper
Similar venues
- Transplantation and Cellular TherapyQ1 · Elsevier BV
- Pediatric Hematology and OncologyQ2 · Taylor & Francis
- Blood Coagulation & FibrinolysisQ3 · Lippincott Williams & Wilkins
- Journal of Pediatric Hematology/OncologyQ3 · Lippincott Williams & Wilkins
- HämostaseologieQ3 · Thieme Medical Publishers (Germany)
- Japanese Journal of Thrombosis and Hemostasis— · Japanese Society on Thrombosis and Hemostasis
Compare it with its peers: Ranked Molecular Biology journals — ranked by Scimago quartile and cites per paper, predatory venues excluded.